Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2026-06-18 @ 8:25 PM
Study NCT ID:
NCT07185256
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Sponsor:
Opus Genetics, Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
OPGx-BEST1 DUO-1001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None